https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51356 Wed 28 Feb 2024 15:52:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45032 P<.001). Conclusions: Vaxtracker is an effective tool for monitoring AEFIs in the 55 to 61 years age group. Participant response rates were high for both surveys, in both treatment arms and for each method of sending the survey. This study indicates that administration of 23vPPV was well-tolerated in this cohort. Vaxtracker has successfully demonstrated its application in the monitoring of adverse events in near-real time following vaccination in people participating in a national clinical trial.]]> Wed 26 Oct 2022 10:52:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36948 Wed 19 Jan 2022 15:16:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51047 Wed 16 Aug 2023 12:01:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12574 Wed 11 Apr 2018 16:48:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22808 Wed 11 Apr 2018 15:09:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:131 Wed 11 Apr 2018 14:42:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34662 Wed 04 Sep 2019 09:48:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54542 Tue 27 Feb 2024 20:40:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43884 Tue 04 Oct 2022 13:45:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38888 Thu 24 Feb 2022 16:17:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46201 Thu 23 Mar 2023 09:43:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55764 Thu 20 Jun 2024 16:35:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27050 Thu 13 Jan 2022 10:31:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50720 Thu 03 Aug 2023 09:33:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1212 Sat 24 Mar 2018 08:28:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10531 Sat 24 Mar 2018 08:13:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20703 Sat 24 Mar 2018 08:06:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17093 Sat 24 Mar 2018 08:05:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17104 Sat 24 Mar 2018 08:02:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28621 Sat 24 Mar 2018 07:38:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22282 In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load.]]> Sat 24 Mar 2018 07:17:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47968 Mon 13 Feb 2023 15:58:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54756 Mon 11 Mar 2024 14:53:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44153 90% probability of a safety signal being detected by AusVaxSafety based on solicited reports for either fever or medical attendance at or before the week ending 28 March 2010, 3 weeks after the start of vaccine distribution. Suspension of the national paediatric influenza vaccination programme as a result of the passive adverse events surveillance operating at the time did not occur until 23 April 2010. Conclusions: Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme, prevention of many febrile convulsions and maintenance of public confidence in influenza vaccination for young children.]]> Mon 10 Oct 2022 09:31:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30652 Mon 09 Oct 2023 14:51:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24722 Mon 06 Jul 2020 08:58:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37947 p < 0.05). Conclusions: Vaccination significantly reduced COVID-19 associated discrimination, but discrimination rates remained high. Among the intended vaccinated respondents, females, the older aged, people with high school and above education level, retirees, migrant workers, and residents in central China were identified as key targets for information campaigns to reduce COVID-19 related discrimination.]]> Mon 05 Jul 2021 19:19:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37949 Mon 05 Jul 2021 19:19:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48660 Fri 24 Mar 2023 16:12:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48457 3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to > 4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58–126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk–benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines.]]> Fri 17 Mar 2023 12:07:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55138 Fri 12 Apr 2024 14:17:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46122 Fri 11 Nov 2022 15:07:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46078 Fri 11 Nov 2022 15:01:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40363 Fri 08 Jul 2022 14:24:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36054 -1 which was considered the protective antibody concentration. There was no statistically significant difference in titers between groups: geometric difference in mean titers 1.13 mIU mL^-1 (95% CI 0.85, 1.51; P = 0.39) and 1.38 mIU mL^-1 (95% CI 0.90, 2.11, P = 0.14) for unadjusted and adjusted analyses, respectively. This study demonstrated that a sun protection intervention study could be performed in a developing-world pediatric vaccination setting. Although the sun protection intervention around the time of vaccination was not associated with a higher antibody level, given the potential importance of such an effect, a larger study should be considered.]]> Fri 03 Dec 2021 10:35:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30500 Fri 01 Apr 2022 09:27:47 AEDT ]]>